Action 2H51 OCUGEN, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Ocugen, Inc. Börse Stuttgart

Actions

2H51

US67577C1053

Temps réel estimé Tradegate
Autres places de cotation
 15:13:00 17/07/2024 		Varia. 5j. Varia. 1 janv.
1,719 EUR -2,44% Graphique intraday de Ocugen, Inc. +7,50% +220,95%
21/06 Le secteur des soins de santé est stable avant le marché vendredi MT
21/06 Ocugen reçoit le feu vert pour participer à l'étude sur la dose élevée de son médicament candidat contre la maladie de Stargardt MT

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Kaival Brands Innovations Group (NASDAQ: KAVL) Secures $6M in Public Offering, Stock Surges Watch VTAK, OCGN, DYAI, INBS
AQ
Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease
GL
Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication
GL
Modifier gene therapy – clinical development and manufacturing considerations
AQ
OCGN DEADLINE TODAY: ROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securities Class Action First Filed by the Firm – OCGN
BU
DEADLINE TODAY: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
BU
OCGN Investors Have Opportunity to Lead Ocugen, Inc. Securities Fraud Lawsuit
PR
MONDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
BU
OCGN Investors Have Opportunity to Lead Ocugen, Inc. Securities Fraud Lawsuit
PR
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen
PR
FINAL DEADLINE NEXT WEEK: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses In Excess of $250,000 to Contact the Firm
PR
OCGN Investors Have Opportunity to Lead Ocugen, Inc. Securities Fraud Lawsuit
PR
OCGN DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important June 10 Deadline in Securities Class Action First Filed by the Firm - OCGN
PR
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen
PR
Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy
GL
Pomerantz Law Firm Announces the Filing of a Class Action Against Ocugen, Inc. - OCGN
PR
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important June 10 Deadline in Securities Class Action First Filed by the Firm - OCGN
NE
OCUGEN SET TO JOIN RUSSELL 3000 INDEX EFFECTIVE JUNE 28, 2024
AQ
Ocugen to Present at BIO International Convention 2024
GL
Ocugen Set to Join Russell 3000® Index Effective June 28, 2024
GL
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action OCGN
  4. Action 2H51
  5. Actualités Ocugen, Inc.
  6. Communiqués